文献速递精神分裂症与精神病性障碍心境障碍

应用全基因组关联研究汇总数据与神经祖细胞药物诱导基因表达谱进行精神疾病药物优先级分析

Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis.
PubMed 文献 · Mol Psychiatry · 2024-07-13

该研究在表型相关组织估计方法(DESE)框架下提出一种新的药物优先级策略,通过分析药物对疾病易感基因的选择性扰动效应,结合全基因组关联研究汇总数据与神经祖细胞药物诱导基因表达谱,对精神分裂症、抑郁症和双相I型障碍的候选药物进行排序。结果显示排名靠前的候选药物中包含多种已知治疗药物,且参与选择性基因扰动分析的疾病易感基因富集于多个生物学上合理的功能条目并与已知治疗药物存在相互作用。作者认为选择性基因扰动分析可作为「一药多靶」范式下为常见精神疾病药物开发排序生物学合理候选药物的有前景的起点。

要点

  • 在DESE框架下提出基于药物对疾病易感基因选择性扰动效应的新药优先级策略。
  • 应用该策略对精神分裂症、抑郁症和双相I型障碍的候选药物进行排序,排名靠前药物中包含已知治疗药物。
  • 参与选择性基因扰动分析的疾病易感基因富集于多个生物学上合理的功能条目并与已知治疗药物相互作用。

核心结论

  • 选择性基因扰动分析可能是在「一药多靶」范式下为常见精神疾病药物开发排序生物学合理候选药物的有前景的起点。

研究设计与样本

  • 研究基于全基因组关联研究汇总数据和神经祖细胞药物诱导基因表达谱,在既往提出的表型相关组织估计方法(DESE)框架下开展药物优先级分析。

主要发现

  • 对精神分裂症、抑郁症和双相I型障碍的候选药物进行排序,排名靠前的候选药物中鉴定出多种已知治疗药物。
  • 参与选择性基因扰动分析的疾病易感基因富集于多个生物学上合理的功能条目,并与已知治疗药物存在相互作用。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Common psychiatric disorders constitute one of the most substantial healthcare burdens worldwide. However, drug development in psychiatry remains hampered partially due to the lack of approaches to estimating drugs that can simultaneously modulate the expression of a nontrivial fraction of disease susceptibility genes. We proposed a new drug prioritization strategy under the framework of our previously proposed phenotype-associated tissues estimation approach (DESE) by investigating the drugs' selective perturbation effect on disease susceptibility genes. Based on the genome-wide association study summary data and drug-induced gene expression profiles of neural progenitor cells, we applied this strategy to prioritize candidate drugs for schizophrenia, depression and bipolar I disorder and identified several known therapeutic drugs among the top-ranked drug candidates. Also, our results revealed that the disease susceptibility genes involved in the selective gene perturbation analysis were enriched with many biologically sensible function terms and interacted with known therapeutic drugs. Our results suggested that selective gene perturbation analysis could be a promising starting point to prioritize biologically sensible drug candidates under the "one drug, multiple targets" paradigm for the drug development of common psychiatric disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Li X, Xue C, Zhu Z, et al. Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis. Mol Psychiatry. 2024. PMID: 39003413. doi:10.1038/s41380-024-02660-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。